NCT05074940View on ClinicalTrials.gov

Amivantamab in Adenoid Cystic Carcinoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

August 5, 2022

Primary Completion Date

August 5, 2025

Study Completion Date

August 5, 2028

Conditions
Salivary Gland Cancer
Interventions
DRUG

Amivantamab

Patients will receive amivantamab at 1050mg weekly for the first cycle and biweekly thereafter (1400mg for patients ≥80kg).

Trial Locations (5)

45219

University of Cincinnati Medical Center, Cincinnati

48109

Rogel Cancer Center - University of Michigan Health, Ann Arbor

63130

Washington University - School of Medicine in St. Louis, St Louis

92093

UC San Diego Moores Cancer Center, La Jolla

02215

Dana Farber Cancer Institute, Boston

All Listed Sponsors
lead

Trisha Wise-Draper

OTHER